Based on an individual’s COVID-19 disease status, they are assigned to one of three groups:
- The educational program, which provides vital sign tracking, prevention techniques and mental health support for those who are asymptomatic.
- The quarantine program, which delivers insights on what to watch for, addresses feelings of fear and isolation, and connects with a healthcare professional for those who have been exposed to COVID-19.
- The in-depth monitoring program, which addresses symptom management, frequent monitoring by a healthcare professional and care coordination for those who have been diagnosed with COVID-19 and who are still at home.
By downloading the program’s app on their personal mobile devices, participants in the program will be able to report key health metrics related to COVID-19 such as body temperature, heart rate and pulse oximetry. In addition, participants report on symptoms of COVID-19 like shortness of breath, fatigue and changes in coughing. Participants benefit from PRA’s nurse-led clinical call center staff, who monitor the information reported through the app on a daily basis. The trained staff can address physical symptoms, as well as the social and psychological impacts they may be experiencing.
“The COVID-19 pandemic has shown the critical need for organizations of all sizes to be able to remotely assist individuals in monitoring their health and wellbeing,” said
The program, which was created by Care Innovations, a
PRA is deploying the COVID-19 Monitoring Program and mobile app to healthcare organizations, large employers, and the company is in discussions with academic institutions, governmental organizations, health departments and other private businesses to roll out the program.
For more information on the COVID-19 Monitoring Program, please contact Care Innovations at https://www.careinnovations.com/contact/ or by phone at 855-885-
ABOUT
PRA (NASDAQ: PRAH) is one of the world’s leading global contract research organizations by revenue, providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes more than 75 offices across
INVESTOR INQUIRIES: InvestorRelations@prahs.com
MEDIA INQUIRIES:
HurstLaurie@prahs.com, +1.919.786.8435
Source:
2020 GlobeNewswire, Inc., source